Arrowhead Research Corporation Agrees To Provide $10 Million Additional Funding For Calando Pharmaceuticals, Inc.; Capital To Be Used To Accelerate Preclinical Trials And Facilitate Collaborations

PASADENA, Calif.--(BUSINESS WIRE)--April 3, 2006--Arrowhead Research Corporation (Nasdaq:ARWR) announced today that it has agreed to contribute up to $10 million in additional capital to its majority-owned subsidiary, Calando Pharmaceuticals, Inc. The additional capital will allow Calando to accelerate preclinical testing of its RNAi therapeutics and to facilitate additional collaborations with large biotech and pharmaceutical companies.